TYME / Tyme Technologies Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38169 TYME TECHNOLOGIES, INC. (Exact name of registrant as specified in

TYME / Tyme Technologies Inc / Hoffman Steve - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 90238J103 (C

As filed with the Securities and Exchange Commission on September 16, 2022

As filed with the Securities and Exchange Commission on September 16, 2022 Registration No.

Amended and Restated Bylaws of Tyme Technologies, Inc.

EX-3.2 Exhibit 3.2 BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective [•], 2022) ARTICLE I OFFICES Tyme Technologies, Inc. (the “Corporation”) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as the Board of Directors may from tim

As filed with the Securities and Exchange Commission on September 16, 2022

POS AM 1 d574274dposam.htm POS AM As filed with the Securities and Exchange Commission on September 16, 2022 Registration No. 333-229104 Registration No. 333-245033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: Form S-3 Registration Statement No. 333-229104 Form S-3 Registration Statement No. 333-245033 under the Securities Act of 1933 T

SYRS / Syros Pharmaceuticals Inc / TYME TECHNOLOGIES, INC. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87184Q107 (CUSIP Number) Tyme Technologies, Inc. 1 Pluckemin Way, Suite 103 Bedminster NJ 07921 (212) 461-2315 (Name, Address and Telephone Number of Person Authorize

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commiss

As filed with the Securities and Exchange Commission on September 16, 2022

As filed with the Securities and Exchange Commission on September 16, 2022 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2022

As filed with the Securities and Exchange Commission on September 16, 2022 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2022

As filed with the Securities and Exchange Commission on September 16, 2022 Registration No.

Amended and Restated Certificate of Incorporation of Tyme Technologies, Inc.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYME TECHNOLOGIES, INC. a Delaware Corporation 1. NAME. The name of the Corporation is Tyme Technologies, Inc. 2. ADDRESS. The address of its registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle 19810. The registered Agent at such address is The Corporation Trust Company. 3

As filed with the Securities and Exchange Commission on September 16, 2022

S-8 POS 1 d397546ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on September 16, 2022 Registration No. 333-219856 Registration No. 333-227077 Registration No. 333-236259 Registration No. 333-255253 Registration No. 333-260912 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: Form S-8 Registration Statement No. 333-21

As filed with the Securities and Exchange Commission on September 16, 2022

As filed with the Securities and Exchange Commission on September 16, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Tyme Technolog

425 1 d330811d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction

Syros and Tyme Technologies Announce Stockholder Approval of Merger — Combined Company to Trade on Nasdaq Under Ticker “SYRS” — — Syros Announces 1-for-10 Reverse Stock Split of Common Stock —

EX-99.1 Exhibit 99.1 Syros and Tyme Technologies Announce Stockholder Approval of Merger — Combined Company to Trade on Nasdaq Under Ticker “SYRS” — — Syros Announces 1-for-10 Reverse Stock Split of Common Stock — CAMBRIDGE, Mass. & BEDMINSTER, N.J., Sept. 15, 2022 – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme T

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Tyme Technologi

425 1 d403048d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction o

TYME Technologies. Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

EX-99.1 Exhibit 99.1 TYME Technologies. Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme BEDMINSTER, New Jersey, September 7, 2022 – Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

Second Amendment to Release Agreement, dated as of September 2, 2022, by and between Tyme Technologies, Inc. and Michael Demurjian.

Exhibit 10.2 Execution Version Second Amendment to Release Agreement This Amendment (the ?Second Amendment?), effective as of September 2, 2022, is entered into by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?), and Michael Demurjian (the ?Stockholder?). WHEREAS, the Stockholder and the Company entered into a Release Agreement on March 15, 2019 (the ?Original Release A

Form of Cooperation Agreement, dated as of September 2, 2022, by and between Tyme Technologies, Inc. and each of its current executive officers.

Exhibit 10.1 [Company Letterhead] September 2, 2022 [Executive] [Address] [Address] Dear []: Under the terms of your April 28, 2022 retention letter agreement (your ?April 2022 Retention Agreement?), you are eligible to receive a retention bonus when Tyme Technologies, Inc. (the ?Company?) completes its merger (the ?Merger?) with Syros Pharmaceuticals, Inc. (?Syros?). The Company is pleased to off

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Tyme Technologi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Form of Nonqualified Stock Option Agreement, adopted on August 24, 2022 under the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors, as amended.

Exhibit 10.1 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT is made on (the ?Date of Grant?), by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?), and (the ?Participant?). WHEREAS, the Company has adopted the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors (the ?

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents Tha UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38169

SYRS / Syros Pharmaceuticals Inc / TYME TECHNOLOGIES, INC. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87184Q107 (CUSIP Number) Tyme Technologies, Inc. 1 Pluckemin Way, Suite 103 Bedminster NJ 07921 (212) 461-2315 (Name, Address and Telephone Number of Person Authorized to Receive Notic

TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT

Exhibit 2 TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (?Syros?), Tyme Technologies, Inc., a Delaware corporation (?Tyme?), and the undersigned stockholder (the ?Stockholder?) of Tyme. RECITALS WHEREAS, concurrently with the execution and delive

TYME / Tyme Technologies Inc / Syros Pharmaceuticals, Inc. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Tyme Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90238J103 (CUSIP Number) Syros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 (617) 744-1340 (Name, Address and Telephone Number of Person Authorized to Receiv

AGREEMENT AND PLAN OF MERGER by and among SYROS PHARMACEUTICALS, INC., TACK ACQUISITION CORP., TYME TECHNOLOGIES, INC. Dated as of July 3, 2022

Exhibit 1 AGREEMENT AND PLAN OF MERGER by and among SYROS PHARMACEUTICALS, INC., TACK ACQUISITION CORP., and TYME TECHNOLOGIES, INC. Dated as of July 3, 2022 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger 2 1.2 Closing 2 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 1.5 Syros Matters 2 ARTICLE II CONVERSION OF SECURITIES 3 2.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 Syros Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio

Agreement and Plan of Merger, dated as of July 3, 2022, by and among Tyme Technologies, Inc., Syros Pharmaceuticals, Inc. and Tack Acquisition Corp.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among SYROS PHARMACEUTICALS, INC., TACK ACQUISITION CORP., and TYME TECHNOLOGIES, INC. Dated as of July 3, 2022 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger 2 1.2 Closing 2 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 1.5 Syros Matters 2 ARTICLE II CONVERSION

Form of Tyme Support Agreement

Exhibit 10.1 TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (?Syros?), Tyme Technologies, Inc., a Delaware corporation (?Tyme?), and the undersigned stockholder (the ?Stockholder?) of Tyme. RECITALS WHEREAS, concurrently with the execution and del

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cas

EX-99.1 Exhibit 99.1 Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H

Form of Syros Support Agreement

Exhibit 10.2 SYROS PHARMACEUTICALS, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Tyme Technologies, Inc. a Delaware corporation (?Tyme?), Syros Pharmaceuticals, Inc., a Delaware corporation (?Syros?), and the undersigned stockholder (the ?Stockholder?) of Syros. RECITALS WHEREAS, concurrently with the execution an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Syros Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Tyme Technologies, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission Fi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission F

Release Agreement, effective March 24, 2022, by and between Steve Hoffman and Tyme Technologies, Inc.

EXHIBIT 10.19 RELEASE AGREEMENT This Release Agreement (this ?Release Agreement?) is made by and between Tyme Technologies, Inc. and Steven Hoffman, as of March 24, 2022. DEFINITIONS 1. As used herein, unless otherwise specified, the term ?Company? shall mean Tyme Technologies, Inc., and all of its affiliates, successors, predecessors, assigns, parents, subsidiaries and divisions (whether incorpor

Voting Agreement, effective April 18, 2022, by and between Michael Demurjian and Tyme Technologies, Inc.

EXHIBIT 10.22 VOTING AGREEMENT VOTING AGREEMENT, dated as of April 18, 2022 (this ?Agreement?), by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?), and Michael Demurjian (the ?Stockholder?). WHEREAS, as of the date hereof, the Stockholder is the Beneficial Owner (as defined below) of 23,708,846 shares of Common Stock, par value $0.0001 per share, of the Company (the ?Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38169 TYME TECHNOLOGIES

Letter Agreement, dated May 11, 2021, by and between Frank Porfido and Tyme Technologies, Inc.****

EXHIBIT 10.25 TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921 May 11, 2021 Mr. Frank Porfido [REDACTED] [REDACTED] Dear Frank: This letter sets forth our agreement with respect to your employment (hereinafter ?letter agreement?) with Tyme Technologies, Inc., a Delaware corporation (the ?Company?). 1.Employment. Your employment with the Company will be upon the terms and con

List of Subsidiaries.

EXHIBIT 21.1 List of Subsidiaries Tyme, Inc., a Delaware Corporation (?Tyme?)

Voting Agreement, effective March 24, 2022, by and between Steve Hoffman and Tyme Technologies, Inc.

EXHIBIT 10.20 VOTING AGREEMENT VOTING AGREEMENT, dated as of March 24, 2022 (this ?Agreement?), by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?), and Steve Hoffman (the ?Stockholder?). WHEREAS, as of the date hereof, the Stockholder is the Beneficial Owner (as defined below) of a number of shares of Common Stock, par value $0.0001 per share, of the Company (the ?Commo

Amendment to Release Agreement, effective April 18, 2022, by and between Michael Demurjian and Tyme Technologies, Inc.

EXHIBIT 10.23 Release Agreement Amendment This Amendment (the ?Amendment?), effective as of April 18, 2022, is entered into by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?), and Michael Demurjian (the ?Stockholder?). WHEREAS, the Stockholder and the Company entered into a Release Agreement on March 15, 2019 (the ?Release Agreement?); WHEREAS, the Company the Stockhold

Form of Indemnification Agreement by and between Tyme Technologies, Inc. and its individual directors and officers.

Exhibit 10.2 TYME TECHNOLOGIES, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?), dated as of April [DATE], 2022, is by and between Tyme Technologies, Inc., a Delaware corporation (the ?Company?) and [NAME OF DIRECTOR/OFFICER] (the ?Indemnitee?). WHEREAS, Indemnitee is [a director/an officer] of the Company; WHEREAS, both the Company and Indemnitee recognize the increase

Amended and Restated By-Laws, effective April 25, 2022.

Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective April 25, 2022) ARTICLE I OFFICES Tyme Technologies, Inc. (the ?Corporation?) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as the Board of Dir

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

Form of Retention Agreement by and between Tyme Technologies, Inc. and certain of its individual officers.

Exhibit 10.3 April 28, 2022 [NAME] [ADDRESS] Dear [NAME]: In exchange for your commitments to Tyme Technologies, Inc. (the ?Company?) and your anticipated future contributions, the Company is pleased to offer you the following retention benefits: 1. Subject to the terms below, upon the closing of a Transaction (as defined below) on or before March 31, 2023 (the ?End Date?), the Company shall pay y

Amended and Restated By-Laws, effective April 25, 2022 (marked).

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective April 25, 2022) ARTICLE I OFFICES Tyme Technologies, Inc. (the ?Corporation?) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as the Board of Dir

Form of Nonqualified Stock Option Agreement, adopted on April 22, 2022 under the Tyme Technologies, Inc. 2015 Equity Incentive Plan.

Exhibit 10.1 Tyme Technologies, Inc. Nonqualified Stock Option Agreement Tyme Technologies, Inc., a Delaware corporation (the ?Company?), pursuant to the Company?s 2015 Equity Incentive Plan (the ?Plan?), has granted to ###PARTICIPANTNAME### (the ?Optionee?) a nonqualified stock option (the ?Option?) to purchase a total of ###TOTALAWARDS### shares (each, a ?Share?) of the common stock, par value $

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

TYME Technologies, Inc. Announces Exploration of Strategic Options

Exhibit 99.1 FOR IMMEDIATE RELEASE TYME Technologies, Inc. Announces Exploration of Strategic Options BEDMINSTER, N.J - (BUSINESS WIRE) March 29, 2022?TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs?), today announced that its Board of Directors has decided to explore potential strategic options to

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents Tha UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

EX-99.1 2 d254929dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results • Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast can

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

TYME / Tyme Technologies Inc / Hoffman Steve - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 902

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer — SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival –

Exhibit 99.1 FOR IMMEDIATE RELEASE TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer ? SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival ? BEDMINSTER, N.J.? (BUSINESS WIRE) January 26, 2022?TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an e

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissio

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissio

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections -- TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for dru

Exhibit 99.1 For Immediate Release TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections - TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for drug screening for antiviral efficacy - - Completed toxicity studies with TYME-19 that are expected to enable an Invest

Form S-8

As filed with the Securities and Exchange Commission on November 9, 2021 Registration No.

TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results – First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/H

Exhibit 99.1 FOR IMMEDIATE RELEASE TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results ? First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor ? ? PanCAN Precision Promise trial to add five new sites

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissio

Resignation Letter of Paul Sturman, dated November 4, 2021.

EXHIBIT 99.1 November 4, 2021 To the Board of Directors of Tyme Technologies, Inc. I am writing to inform you of my decision to resign my position on the Board of Tyme Technologies, Inc. Due to recent changes in my professional career, I have chosen to step back from current commitments as I head down a different professional path. It has been a pleasure being a part of the Tyme Board. I am proud

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb

Amended and Restated By-Laws, effective August 24, 2021.

EX-3.1 2 d528599dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective August 24, 2021) ARTICLE I OFFICES Tyme Technologies, Inc. (the “Corporation”) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the Stat

Amended and Restated By-Laws, effective August 24, 2021 (marked).

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective April 2 August 24, 2018 2021) ARTICLE I OFFICES Tyme Technologies, Inc. (the ?Corporation?) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as th

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

Amended and Restated 2016 Stock Option Plan for Non-Employee Directors of the Registrant, effective August 24, 2021.

EX-10.1 4 d528599dex101.htm EX-10.1 Exhibit 10.1 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS As Amended and Restated Effective August 24, 2021 TABLE OF CONTENTS Page 1. Purpose 1 2. Definitions 1 3. Administration 3 4. Eligibility 3 5. Stock Subject to the Plan 3 6. Non-Employee Director Options 4 7. General Provisions 6 -i- Tyme Technologies, Inc. 2016 Stock Option P

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results – Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical s

Exhibit 99.1 FOR IMMEDIATE RELEASE TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results ? Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings ? - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission F

List of Subsidiaries.

EXHIBIT 21.1 List of Subsidiaries Tyme, Inc., a Delaware Corporation (?Tyme?)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38169 TYME TECHNOLOGIES

Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial with Georgetown University, and Reports Fiscal Year 2021 Financial Results – Comprehensive strategic review identified breast cancer as a priority indication for develop

Exhibit 99.1 Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial with Georgetown University, and Reports Fiscal Year 2021 Financial Results ? Comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas - Recently appointed acting Chief Medical

Separation and General Release Agreement, effective March 31, 2021, by and between Giuseppe Del Priore and Tyme Technologies, Inc.

EXHIBIT 10.18 C O N F I D E N T I A L SEPARATION AND GENERAL RELEASE AGREEMENT This SEPARATION AND GENERAL RELEASE AGREEMENT (?Agreement?) is made and entered into by and between Tyme Technologies, Inc. (the ?Company?) and Giuseppe Del Priore (?Employee?). Employee and the Company shall be referred to herein as the ?Parties? or, each separately, a ?Party.? WHEREAS, Employee is employed by the Comp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission Fi

Form S-8

As filed with the Securities and Exchange Commission on April 15, 2021 Registration No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commission F

TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

EX-99.1 Exhibit 99.1 TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer BEDMINSTER, N.J.—(BUSINESS WIRE)—Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Torn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 902

Form of Securities Purchase Agreement, dated February 4, 2021.

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 4, 2021, between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commi

TYME TECHNOLOGIES, INC. 40,000,000 shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-245033 Prospectus Supplement (to Prospectus dated September 2, 2020) TYME TECHNOLOGIES, INC. 40,000,000 shares Common Stock We are offering to certain healthcare-focused institutional investors and other institutional investors 40,000,000 shares of our common stock, $0.0001 par value per share, in this offering at a purc

430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC

EX-99.1 Exhibit 99.1 Execution Version February 3, 2021 STRICTLY CONFIDENTIAL Tyme Technologies, Inc. 1 Pluckemin Way, Suite 103 Bedminster NJ 07921 Attn: Richard Cunningham, Chief Executive Officer Dear Mr. Cunningham: This letter agreement (this “Agreement”) constitutes the agreement between Tyme Technologies, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh

Letter Agreement, dated November 24, 2020, by and between Richard Cunningham and Tyme Technologies, Inc.***

Execution Version EXHIBIT 10.1 TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921 November 24, 2020 Mr. Richard Cunningham [REDACTED] [REDACTED] Dear Richard: This letter sets forth our agreement with respect to your employment (hereinafter “letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (the “Company”). 1.Employment. Your employment with the Company w

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Letter Agreement, dated November 24, 2020, by and between Steve Hoffman and Tyme Technologies, Inc.***

Execution Version EXHIBIT 10.2 TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921 November 24, 2020 Mr. Steven Hoffman [REDACTED] [REDACTED] Dear Steven: This amended and restated letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company”). RECITALS: WHEREAS, you previously enter

TYME Builds Leadership Team with Announcement of New CEO

EX-99.1 Exhibit 99.1 TYME Builds Leadership Team with Announcement of New CEO • Steve Hoffman, TYME’s Long-Time Chairman and Chief Executive Officer, to Remain Chairman and Chief Science Officer • Richie Cunningham, to Succeed Steve Hoffman as Chief Executive Officer BEDMINSTER, NJ, November 30, 2020 — (BUSINESS NEWSWIRE) – Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

Letter Agreement, dated September 20, 2020, by and between Ben R. Taylor and Tyme Technologies, Inc.***

EXHIBIT 10.2 Ben Taylor September 20, 2020 Dear Mr. Taylor, This letter agreement (this “Agreement”) sets forth the terms and conditions whereby you (“Consultant” or “you”), agrees to provide certain services to Tyme Technologies, Inc., a Delaware corporation, and its affiliates (collectively, the “Company”). 1. SERVICES. 1.1 Following your resignation from the Company as President and Chief Finan

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

TYME TECHNOLOGIES, INC. 2,166,667 Shares of Common Stock Issuable Upon the Exercise of Warrants to Purchase Shares of Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-245033 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2020) TYME TECHNOLOGIES, INC. 2,166,667 Shares of Common Stock Issuable Upon the Exercise of Warrants to Purchase Shares of Common Stock This prospectus relates to the offer and sale by us of up to 2,166,667 shares of our common stock issuable from time to ti

TYME TECHNOLOGIES, INC. Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-245033 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2020) TYME TECHNOLOGIES, INC. $22,155,807 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sale Agreement, dated October 18, 2019, as amended on August 12, 2020, with Jefferies LLC, or Jefferies, relating to shares of our common stock

- S-3/A

S-3/A Table of Contents As filed with the Securities and Exchange Commission on September 2, 2020 Registration No.

-

CORRESP TYME TECHNOLOGIES, INC. 1 Pluckemin Way, Suite 103, Bedminster, NJ 07921 Telephone: (212) 461-2315 VIA EDGAR August 31, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tyme Technologies, Inc. Registration Statement on Form S-3 File No. 333-245033 Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securities A

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

Form of Subordinated Indenture between the Company and one or more trustees to be named.

EX-4.8 Exhibit 4.8 TYME TECHNOLOGIES, INC. TO [] Trustee INDENTURE Dated as of [] Subordinated Debt Securities Tyme Technologies, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [] Trust Indenture Act Section Indenture Section §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 §311(a) 613 (b) 613 §312(a) 701, 702

Power of Attorney (contained in the signature pages of this registration statement as previously filed).

S-3 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2020 Registration No.

Form of Senior Indenture between the Company and one or more trustees to be named.

EX-4.6 Exhibit 4.6 TYME TECHNOLOGIES, INC. TO [] Trustee INDENTURE Dated as of [] Senior Debt Securities Tyme Technologies, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [ ] Trust Indenture Act Section Indenture Section §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 §311(a) 613 (b) 613 §312(a) 701, 702(a) (

Amendment No. 1, dated August 12, 2020, to the Open Market Sale Agreement, dated as of October 18, 2019, by and between Tyme Technologies, Inc. and Jefferies LLC. (Filed herewith.)

EX-1.2 Exhibit 1.2 AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENT SM August 12, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”) are parties to that certain Open Market Sale AgreementSM, dated October 18, 2019, (the “Original Agreement”). All capitalized terms not def

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commis

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commiss

TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer

EX-99.1 Exhibit 99.1 TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer • SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events • TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancre

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results

EX-99.1 Exhibit 99.1 TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results • New Preclinical Data Supporting SM-88 Mechanism of Action Presented at AACR 2020 • TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer • PanCAN enrolling patients in its Precision PromiseSM adap

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

July 10, 2020

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commissi

List of Subsidiaries.

EXHIBIT 21.1 List of Subsidiaries Tyme, Inc., a Delaware Corporation (“Tyme”) Luminant Biosciences, LLC (a wholly-owned subsidiary of Tyme)

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38169 TYME TECHNOLOGIES

Employment Agreement, dated as of October 9, 2018, by and between Michele Korfin and Tyme Technologies, Inc.

DocuSign Envelope ID: 4E0DE264-57B1-499F-AFA7-F6AD50F64C1A EXHIBIT 10.18 TYME TECHNOLOGIES, INC. 17 State Street – 7th Floor New York, New York 10004 October 9, 2018 Ms. Michele Korfin 202 Meadow View Lane Glen Garner. NJ 08826 Dear Michele: This letter sets forth our agreement with respect to your employment (hereinafter “letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (th

Co-Promotion Agreement with Eagle Pharmaceuticals, Inc., dated January 7, 2020.****

EXHIBIT 10.20 EXECUTION VERSION CO-PROMOTION AGREEMENT by and between TYME TECHNOLOGIES, INC. And EAGLE PHARMACEUTICALS, INC. January 7, 2020 TABLE OF CONTENTS Page ARTICLE 1DEFINITIONS1 ARTICLE 2RIGHTS AND OBLIGATIONS7 2.1 Engagement; Grant of Rights7 2.2 Retention of Rights7 2.3 Non-Competition; Non-Solicitation8 2.4 TYME Trademarks and Copyrights8 ARTICLE 3JOINT SALES OPERATIONS COMMITTEE8 3.1

Form of Share Leak-Out Agreement, dated May 20, 2020

EX-10.3 Exhibit 10.3 [Holder] [Address] [Address] [Address] May , 2020 Dear Sirs: This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with that certain understanding by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”) and the undersigned (“Holder”). Reference is hereby made to that certain Exchange Agreement, dated May , 2020 (the “Exchange

Form of Share Exchange Agreement, dated May 20, 2020.

EX-10.1 Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (the “Agreement”) is entered into as of the day of May, 2020, by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and the undersigned holder of the Existing Warrant (as defined below) (the “Holder”), with reference to the following facts: A. The Holder has previously acquired that certain Warrant to Purchas

Form of Warrant Leak-Out Agreement, dated May 20, 2020

EX-10.4 Exhibit 10.4 [Holder] [Address] [Address] [Address] May , 2020 Dear Sirs: This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with that certain understanding by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”) and the undersigned (“Holder”). Reference is hereby made to that certain Exchange Agreement, dated May , 2020 (the “Exchange

Form of New Warrant, dated May 20, 2020

EX-4.1 Exhibit 4.1 THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. TYME TECHNOLOGIES, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: 2020-001 Date of Issuance: May [ ], 2020 (“Issuance Date”) Tyme Technologies, Inc., a Delaware corporation (the “Company”), hereby cert

Form of Warrant Exchange Agreement, dated May 20, 2020

EX-10.2 Exhibit 10.2 EXCHANGE AGREEMENT This Exchange Agreement (the “Agreement”) is entered into as of the day of May, 2020, by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and the undersigned holder of the Existing Warrant (as defined below) (the “Holder”), with reference to the following facts: A. The Holder has previously acquired that certain Warrant to Purchas

TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results

EX-99.1 Exhibit 99.1 TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results • TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer • PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancre

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

TYME / Tyme Technologies, Inc. / Hoffman Steve - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 902

TYME / Tyme Technologies, Inc. 10-Q - Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Form S-8

Form S-8 As filed with the Securities and Exchange Commission on February 5, 2020 Registration No.

TYME / Tyme Technologies, Inc. / EAGLE PHARMACEUTICALS, INC. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tyme Technologies, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90238J103 (CUSIP Number) January 7, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

Registration Rights Agreement, dated January 7, 2020, between the Company and Eagle.

EX-4.1 Exhibit 4.1 Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of January 7, 2020 by and between Tyme Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Eagle Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “

Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer

EX-99.1 Exhibit 99.1 Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer • Collaboration leverages combined capabilities of Tyme Technologies and Eagle Pharmaceuticals to maximize potential of oral SM-88 by advancing pivotal trials and commercialization. • TYME recently launched the TYME-88-PANC piv

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

Certificate of Designation of Series A Convertible Preferred Stock, dated January 7, 2020, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on January 8, 2020.

EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF TYME TECHNOLOGIES, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Tyme Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, does h

Securities Purchase Agreement, dated January 7, 2020, between the Company and Eagle.

EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement, dated as of January 7, 2020 (the “Agreement”), is by and between Tyme Technologies, Inc., a Delaware corporation with its principal offices at 17 State Street, 7th Floor, New York, NY 10004 (the “Company”), and Eagle Pharmaceuticals, Inc., a Delaware corporation with its principal offices at 50

Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commis

TYME / Tyme Technologies, Inc. 10-Q - Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

Open Market Sale Agreement, dated as of October 18, 2019, by and between Tyme Technologies, Inc. and Jefferies LLC

EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 18, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tyme Technologies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s

TYME TECHNOLOGIES, INC. Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-211489 PROSPECTUS SUPPLEMENT (To Prospectus dated August 16, 2017) TYME TECHNOLOGIES, INC. $30,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus

TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

EX-99.1 Exhibit 99.1 TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results • TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer • TYME Presented Final Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouragi

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 filed with the SEC on August 8, 2019;

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

The information from our definitive proxy statement filed on July 16, 2019 specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended March 31, 2019

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

TYME Conference Call Participants General Comments Steve Hoffman, Chairman & Chief Executive Officer Overview of TYME-88-Panc Study Michele Korfin, RPh, MBA, Chief Operating Officer ESMO GI Results Giuseppe Del Priore, MD, MPH, Chief Medical Officer

EX-99.1 ESMO GI Conference Call July 9, 2019 NASDAQ: TYME Exhibit 99.1 TYME Conference Call Participants General Comments Steve Hoffman, Chairman & Chief Executive Officer Overview of TYME-88-Panc Study Michele Korfin, RPh, MBA, Chief Operating Officer ESMO GI Results Giuseppe Del Priore, MD, MPH, Chief Medical Officer Observations from a Key Opinion Leader Manuel Hidalgo, MD, Chief of the Divisio

TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

EX-99.1 Exhibit 99.1 TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer • In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 • Efficacy indicators showed strong correlation with greater overall survival (OS). These

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

our Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC on June 12, 2019

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38169 TYME TECHNOLOGIES

Release Agreement, dated as of March 15, 2019, between Tyme Technologies, Inc. and Michael Demurjian.

Exhibit 10.14 RELEASE AGREEMENT This Release Agreement (this “Release Agreement”) is made by and between Tyme Technologies, Inc. and Michael Demurjian on this 15th day of March, 2019. DEFINITIONS 1. As used herein, unless otherwise specified, the term “Company” shall mean Tyme Technologies, Inc., and all of its affiliates, successors, predecessors, assigns, parents, subsidiaries and divisions (whe

Exhibit 4.6 to our Annual Report on Form 10-K

Exhibit 4.6 DESCRIPTION OF COMMON STOCK We are authorized to issue up to 300,000,000 shares of common stock, $0.0001 par value per share. Voting Each holder of common stock is entitled to one vote per share on all matters requiring a vote of the security holders, including the election of directors. We do not have cumulative voting rights. Dividends Holders of common stock are entitled to receive

List of Subsidiaries.

EXHIBIT 21.1 List of Subsidiaries Tyme, Inc., a Delaware Corporation (“Tyme”) Luminant Biosciences, LLC (a wholly-owned subsidiary of Tyme)

Form of Nonqualified Stock Option Agreement under the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors.

Exhibit 10.11 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”). WHEREAS, the Company has adopted the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors (the

Letter Agreement, dated as of September 10, 2018, between Tyme Technologies, Inc. and James Biehl

EXHIBIT 10.19 TYME TECHNOLOGIES, INC. 17 State Street – 7th Floor New York, New York 10004 September 10, 2018 Mr. James Biehl Dear Jim: This letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company”). 1.Employment. You will be employed by the Company upon the terms and conditions set forth in this l

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

EX-99.1 Exhibit 99.1 TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results • Tyme-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019 • Single Agent SM-88 (Racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical Testing with Results to Be Presented in Second Half 2019 • Plan

TYME Conference Call Participants Business Highlights and 2019 Milestones Steve Hoffman, Chairman & Chief Executive Officer Clinical Development Progress Michele Korfin, R.Ph., M.B.A., Chief Operating Officer Giuseppe Del Priore, M.D., M.P.H., Chief

EX-99.2 4Q & FY 2019 Conference Call May 29, 2019 NASDAQ: TYME Exhibit 99.2 TYME Conference Call Participants Business Highlights and 2019 Milestones Steve Hoffman, Chairman & Chief Executive Officer Clinical Development Progress Michele Korfin, R.Ph., M.B.A., Chief Operating Officer Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer Corporate and Financial Update Ben R. Taylor, President &

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers ● Complements strong patent portfolio covering SM-88 in use with other conditioning agents

EX-99.1 Exhibit 99.1 TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers ● Complements strong patent portfolio covering SM-88 in use with other conditioning agents NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) – Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced to

Form of Warrant

EX-4.1 Exhibit 4.1 [FORM OF WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. TYME TECHNOLOGIES, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Date of Issuance: April 2, 2019 (“Issuance Date”) Tyme Technologies, Inc., a Delaware corporation (the “Company”), he

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Co

Underwriting Agreement, dated March 28, 2019, by and between Tyme Technologies, Inc. and Canaccord Genuity LLC

EX-1.1 Exhibit 1.1 Tyme Technologies, Inc. 8,000,000 Shares of Common Stock and Warrants to Purchase up to 8,000,000 Shares of Common Stock Underwriting Agreement March 28, 2019 Canaccord Genuity LLC As Representative of the Several Underwriters 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Tyme Technologies, Inc., a Delaware corporation (the “Company”), proposes to

TYME TECHNOLOGIES, INC. 8,000,000 Shares of Common Stock Warrants to Purchase 8,000,000 Shares of Common Stock

424B2 Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-211489 PROSPECTUS SUPPLEMENT (to Prospectus dated August 16, 2017) TYME TECHNOLOGIES, INC. 8,000,000 Shares of Common Stock Warrants to Purchase 8,000,000 Shares of Common Stock We are offering 8,000,000 shares of our common stock, par value $0.0001 per share, and warrants to purchase 8,000,000 shares of our common stock

Subject to Completion. Dated March 28, 2019.

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-211489 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Completion. Dated March 28, 2019. P

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Co

Form of Notice to Warrant Holders.

EX-10.1 Exhibit 10.1 NOTICE OF AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK OF TYME TECHNOLOGIES, INC. THIS NOTICE OF AMENDMENT (this “Amendment”), dated as of March 15, 2019, to the Warrant to Purchase Common Stock of Tyme Technologies, Inc. (the “Warrant”), originally issued pursuant that certain Stock Purchase Agreement between Tyme Technologies, Inc. (the “Company”) and (the “Holder”), dated

TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer

EX-99.1 Exhibit 99.1 TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer NEW YORK, February 25, 2019 (GLOBE NEWSWIRE) – Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design guidance for a registrational trial from the U.S. Food and Drug Administration (F

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

TYME TECHNOLOGIES, INC. 11,209,072 Shares of Common Stock

424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-229104 Prospectus TYME TECHNOLOGIES, INC. 11,209,072 Shares of Common Stock This prospectus will be used from time to time by the selling security holders named in this prospectus to resell up to 11,209,072 shares of common stock, 4,469,836 of which are issuable upon the exercise of outstanding warrants (the “Securities”). The selling sec

TYME / Tyme Technologies, Inc. AMENDMENT NO. 1 TO FORM S-3

Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on February 20, 2019 Registration No. 333-229104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TYME TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 45-3864597 (State or other

TYME / Tyme Technologies, Inc. CORRESP

SEC Correspondence TYME TECHNOLOGIES, INC. 17 State Street – 7th Floor New York, New York 10004 (212) 461-2315 VIA EDGAR February 20, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tyme Technologies, Inc. Registration Statement on Form S-3 File No. 333-229104 Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securi

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

TYME Reports Encouraging

EX-99.1 Exhibit 99.1 TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer • SM-88 therapy did not exhibit typical side effects associated with hormonal castration from androgen-deprivation therapy (ADT) • 87% of patients (20/23) remained free of radiographic progression • After 12 weeks,

TYME / Tyme Technologies, Inc. / Demurjian Michael - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 902

TYME / Tyme Technologies, Inc. / Hoffman Steve - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240. 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Tyme Technologies, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 902

TYME / Tyme Technologies, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Regulation FD Disclosure

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

TYME’s Novel Metabolic-Based Cancer Therapy,

EX-99.1 Exhibit 99.1 TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer • 68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last therapy) • Of 14 patients receiving SM-88 as t

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

TYME IS AN EMERGING BIOTECHNOLOGY COMPANY COMMITTED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF INNOVATIVE METABOLIC-BASED THERAPIES ADVANCING MEDICAL INNOVATION THAT HELPS CANCER PATIENTS LIVE LONGER BETTER LIVES AND REDUCING THE BURDEN ON HEALTHC

EX-99.2 January 2019 NASDAQ: TYME Exhibit 99.2 TYME IS AN EMERGING BIOTECHNOLOGY COMPANY COMMITTED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF INNOVATIVE METABOLIC-BASED THERAPIES ADVANCING MEDICAL INNOVATION THAT HELPS CANCER PATIENTS LIVE LONGER BETTER LIVES AND REDUCING THE BURDEN ON HEALTHCARE Overview Steve Hoffman, Chairman & CEO Ben R. Taylor, President & CFO Benchmarking 3rd Line Pancrea

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2019 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

Tyme Schedules Conference Call to Discuss

EX-99.1 Exhibit 99.1 Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18th NEW YORK , Jan. 15, 2019 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ: TYME ), a clinical-stage oncology biotechnology company developing metabolically-based cancer therapeutics, today announced that its management team will hold a conference call with anal

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

TYME / Tyme Technologies, Inc. FORM S-3

Form S-3 As filed with the Securities and Exchange Commission on December 31, 2018 Registration No.

Tyme Technologies, Inc. Corporate Overview (NASDAQ: TYME) SM-88 SM-88 (our lead oral product) has shown anti-tumor activity across 15 hematologic and solid cancers Two monotherapy Phase II studies for prostate and pancreatic cancer ongoing Two pivota

EX-99.1 Tyme Logicum | Scientia | Humanitas November 2018 NASDAQ: TYME Exhibit 99.1 Tyme Technologies, Inc. Corporate Overview (NASDAQ: TYME) SM-88 SM-88 (our lead oral product) has shown anti-tumor activity across 15 hematologic and solid cancers Two monotherapy Phase II studies for prostate and pancreatic cancer ongoing Two pivotal cohorts in pancreatic cancer expected to begin during 2019 Phase

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019

EX-99.1 Exhibit 99.1 Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019 November 5, 2018 at 7:30 AM EDT • SM-88 to be included in pivotal Precision Promise pancreatic cancer trial led by Pancreatic Cancer Action Network (PanCAN) expected to commence in the first half of 2019 • Interim data for SM-88 from Phase II pancreatic cancer trial expected in January 2019 • Tyme continues to buil

TYME / Tyme Technologies, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb

Regulation FD Disclosure

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (

to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision Promise

EX-99.1 2 d636498dex991.htm EX-99.1 Exhibit 99.1 Tyme’s SM-88 to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision PromiseSM” Adaptive Phase II/III Pancreatic Cancer Trial Platform • Innovative trial design intended to accelerate development of pancreatic cancer therapies • Potential pivotal pathway for SM-88 monotherapy in the second-line pancreatic cancer setting • Al

Results of Operations and Financial Condition, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors

EX-99.1 Exhibit 99.1 Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors • Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors • James Biehl appointed as Chief Legal Officer of Tyme; to step down from the board of directors NEW YORK, September 18, 2018 (GLOBE NEWSWIRE) – Tyme Technologies, Inc. (NASDAQ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation)

Tyme Exceeds Enrollment Expectations for the Phase II Trial of

EX-99.1 Exhibit 99.1 Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer September 5, 2018 at 8:00 AM EDT NEW YORK, September 5, 2018 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s P

Form S-8

Form S-8 As filed with the Securities and Exchange Commission on August 28, 2018 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (C

Form of Amendment to Nonqualified Stock Option Agreement under the Tyme Technologies, Inc. 2015 Equity Incentive Plan.

Exhibit 10.6 Tyme Technologies, Inc. Amendment to Nonqualified Stock Option Agreement This Amendment to Nonqualified Stock Option Agreement (the “Amendment”), dated , 2018 (the “Effective Date”) is made by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Optionee”). WHEREAS, on May 24, 2018 (the “Date of Grant”), the Company, pursuant to the Company’s 2015 Equ

Amended Letter Agreement, dated July 30, 2018, by and between Ben R. Taylor and Tyme Technologies, Inc.

Exhibit 10.2 TYME TECHNOLOGIES, INC. 17 State Street – 7th Floor New York, New York 10004 July 30, 2018 Ben Roberts Taylor Dear Ben: This letter sets forth our amended and restated agreement with respect to your employment (hereinafter “amended letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (the “Company”). 1.Employment. You will continue your employment with the Company u

Form of Stock Option Agreement under the Tyme Technologies, Inc. 2015 Equity Incentive Plan.

Exhibit 10.7 Tyme Technologies, Inc. [Nonqualified] [Incentive] Stock Option Agreement Tyme Technologies, Inc., a Delaware corporation (the “Company”), pursuant to the Company’s 2015 Equity Incentive Plan (the “Plan”), has granted to [NAME OF EMPLOYEE] (the “Optionee”) [a nonqualified] [an incentive] stock option (the “Option”) to purchase a total of shares (each, a “Share”) of the common stock, p

Amended and Restated Nonqualified Stock Option Agreement, dated July 30, 2018, by and between Tyme Technologies, Inc. and Jonathan Eckard.

Exhibit 10.5 Tyme Technologies, Inc. Amended & Restated Nonqualified Stock Option Agreement This Amended and Restated Nonqualified Stock Option Agreement (the “Agreement”), dated July 30, 2018, (the “Effective Date”) is made by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Jonathan Eckard (the “Optionee”). WHEREAS, on August 1, 2017 (the “Date of Grant”), the Com

Amended and Restated Nonqualified Stock Option Agreement, dated July 30, 2018, by and between Tyme Technologies, Inc. and Ben R. Taylor.

Exhibit 10.3 Tyme Technologies, Inc. Amended & Restated Nonqualified Stock Option Agreement This Amended and Restated Nonqualified Stock Option Agreement (the “Agreement”), dated July 30, 2018, (the “Effective Date”) is made by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Ben R. Taylor (the “Optionee”). WHEREAS, on March 27, 2017 (the “Date of Grant”), the Compa

TYME / Tyme Technologies, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Amended Letter Agreement, dated July 30, 2018, by and between Jonathan Eckard and Tyme Technologies, Inc.

Exhibit 10.4 TYME TECHNOLOGIES, INC. 17 State Street – 7th Floor New York, New York 10004 July 30, 2018 Jonathan Eckard Dear Jon: This letter sets forth our amended and restated agreement with respect to your employment (hereinafter “amended letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (the “Company”). 1.Employment. You will continue your employment with the Company upon

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Com

Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019

EX-99.1 Exhibit 99.1 Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019 July 30, 2018 at 7:30 AM EDT NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended June 30, 2018. The Company’s

TYME / Tyme Technologies, Inc. DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

List of Subsidiaries.

EX-21.1 EXHIBIT 21.1 List of Subsidiaries Tyme, Inc., a Delaware Corporation (“Tyme”) Luminant Biosciences, LLC (a wholly-owned subsidiary of Tyme)

TYME / Tyme Technologies, Inc. FORM 10-K (Annual Report)

Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Amended and Restated By-Laws of Tyme Technologies, Inc., effective April 2, 2018. (marked copy.)

EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective April 2, 2018) BY-LAWS ARTICLE I OFFICES Tyme Technologies, Inc. (the “Corporation”) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as th

Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations a

EX-99.1 SM-88 First Human Study (FHS) and Compassionate Use Program Clinical Analysis June 2018 NASDAQ: TYME Exhibit 99.1 Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject t

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Com

TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS As Amended and Restated Effective May 24, 2018 TABLE OF CONTENTS Page 1. Purpose 1 2. Definitions 1 3. Administration 3 4. Eligibility 3 5. Stock Subject to the Plan 3 6. Non-E

EX-99.1 Exhibit 99.1 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS As Amended and Restated Effective May 24, 2018 TABLE OF CONTENTS Page 1. Purpose 1 2. Definitions 1 3. Administration 3 4. Eligibility 3 5. Stock Subject to the Plan 3 6. Non-Employee Director Options 4 7. General Provisions 6 -i- Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors

TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT

EX-99.2 Exhibit 99.2 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”). WHEREAS, the Company has adopted the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employ

TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT

EX-99.3 Exhibit 99.3 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”). WHEREAS, the Company has adopted the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Comm

TYME / Tyme Technologies, Inc. / Brown Christopher F - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. ) Tyme Technologies, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 par value (Title of Class of Securities) 90238J103 (CUSIP Number) November 3, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018

EX-99.1 Exhibit 99.1 Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018 NEW YORK, April 9, 2018 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal year ended March 31, 2018. The Company’s lead clinical program, SM-88, is a nov

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Com

TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS As Amended and Restated Effective February 5, 2018 TABLE OF CONTENTS Page 1. Purpose 1 2. Definitions 1 3. Administration 3 4. Eligibility 3 5. Stock Subject to the Plan 3 6. N

EX-99.2 Exhibit 99.2 TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS As Amended and Restated Effective February 5, 2018 TABLE OF CONTENTS Page 1. Purpose 1 2. Definitions 1 3. Administration 3 4. Eligibility 3 5. Stock Subject to the Plan 3 6. Non-Employee Director Options 4 7. General Provisions 5 -i- Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Direct

Amended and Restated By-Laws of Tyme Technologies, Inc., effective April 2, 2018. (Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K, filed with the SEC on April 2, 2018.)

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF TYME TECHNOLOGIES, INC. (Incorporated Under the Laws of the State of Delaware) (effective April 2, 2018) ARTICLE I OFFICES Tyme Technologies, Inc. (the “Corporation”) shall maintain a registered office in the State of Delaware. The Corporation may also have other offices at such places, either within or without the State of Delaware, as the Board

AMENDMENT NO. 2 TO THE TYME TECHNOLOGIES, INC. 2015 EQUITY INCENTIVE PLAN

EX-99.1 Exhibit 99.1 AMENDMENT NO. 2 TO THE TYME TECHNOLOGIES, INC. 2015 EQUITY INCENTIVE PLAN The Tyme Technologies, Inc. 2015 Equity Incentive Plan (the “Plan”) is hereby amended on this day of February, 2018, to reflect the following provisions: 1. The definition of “Fair Market Value” in Section 1.2 of the Plan is hereby amended to read in its entirety as follows: “Fair Market Value” as of a p

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tyme Technologies, Inc., effective April 2, 2018 (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on April 2, 2018.)

EX-3.1 Exhibit 3.1 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Tyme Technologies, Inc. Tyme Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby adopts this Certificate of Amendment (this “Certificate of Amendment”), which amends its Amended and Restated Cert

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Com

NONQUALIFIED STOCK OPTION AWARD AGREEMENT

EX-99.4 Exhibit 99.4 NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”). WHEREAS, the Company has adopted the Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors (the “Plan”); and WHEREAS, the Company desires to grant to the Participa

Tyme Technologies, Inc. Nonqualified Stock Option Agreement

EX-99.3 Exhibit 99.3 Tyme Technologies, Inc. Nonqualified Stock Option Agreement Tyme Technologies, Inc., a Delaware corporation (the “Company”), pursuant to the Tyme Technologies, Inc. 2015 Equity Incentive Plan (the “Plan”), has granted to (the “Optionee”) a nonqualified stock option (the “Option”) to purchase a total of shares (each, a “Share”) of the common stock (the “Common Stock”) of the Co

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Co

Initial Clinical Sites Expected to Open Over the Coming Weeks

EX-99.1 Exhibit 99.1 FDA Acceptance of IND for Tyme to Begin Phase 2 Trial in Pancreatic Cancer March 14, 2018 at 8:00 AM EDT Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK, March 14, 2018 – Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (“IND”) appl

TYME / Tyme Technologies, Inc. DEF 14C

DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Tyme Technologies, Inc. (Name of

Underwriting Agreement, dated March 1, 2018, by and among Tyme Technologies, Inc., Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity Inc.

EX-1.1 Exhibit 1.1 Tyme Technologies, Inc. 9 million Shares of Common Stock Underwriting Agreement March 1, 2018 Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated Canaccord Genuity Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2018 Tyme Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38169 45-3864597 (State or other jurisdiction of incorporation) (Com

9,000,000 Shares TYME TECHNOLOGIES, INC. Common Stock

424B2 Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-211489 PROSPECTUS SUPPLEMENT (to Prospectus dated August 16, 2017) 9,000,000 Shares TYME TECHNOLOGIES, INC. Common Stock We are offering 9 million shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “TYME.” On March 1, 2018, the last reported s

12,000,000 Shares TYME TECHNOLOGIES, INC. Common Stock

424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.